Circulating Tumor Cells in Cancer Therapy: Are we off Target?

Author(s): C. Raimondi, G. Naso, A. Gradilone, W. Gianni, E. Cortesi, P. Gazzaniga

Journal Name: Current Cancer Drug Targets

Volume 10 , Issue 5 , 2010

Become EABM
Become Reviewer
Call for Editor


What clinical oncologists learned about the metastatic process, is that it is the main cause of cancer-related deaths. What scientists learned about the metastatic disease, is that it is due to a highly selective process, which involves a minority of tumor cells that are able to survive within the bloodstream, and to initiate a new growth in distant sites. These cells “in transit” are known as circulating tumor cells (CTCs). Although their nature is not fully understood, what is widely accepted, is that they are drug resistant, and that their presence may represent the main reason for treatment failure. Despite this body of evidence, the pharmacological approach against cancer, with both chemotherapic and biological drugs, is still targeted on the primary tumor, raising the question as to whether we are missing the target. Targeting circulating tumor cells, may represent a new promising approach to individualize anticancer therapy.

Keywords: Circulating tumor cells, chemotherapy, target therapy, drug resistance

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Published on: 01 March, 2012
Page: [509 - 518]
Pages: 10
DOI: 10.2174/156800910791517163
Price: $65

Article Metrics

PDF: 29